Inequalities and mental health during the Coronavirus pandemic in the UK: a mixed-methods exploration.

Inequalities and mental health during the Coronavirus pandemic in the UK: a mixed-methods exploration.

Publication date: Sep 20, 2023

The World Health Organisation declared the novel Coronavirus disease (COVID-19) a global pandemic on 11th March 2020. Since then, the world has been firmly in its grip. At the time of writing, there were more than 767,972,961 million confirmed cases and over 6,950,655 million deaths. While the main policy focus has been on controlling the virus and ensuring vaccine roll-out and uptake, the population mental health impacts of the pandemic are expected to be long-term, with certain population groups affected more than others. The overall objectives of our ‘Coronavirus: Mental Health and the Pandemic’ study were to explore UK adults’ experiences of the Coronavirus pandemic and to gain insights into the mental health impacts, population-level changes over time, current and future mental health needs, and how these can best be addressed. The wider mixed-methods study consisted of repeated cross-sectional surveys and embedded qualitative sub-studies including in-depth interviews and focus group discussions with the wider UK adult population. For this particular inequalities and mental health sub-study, we used mixed methods data from our cross-sectional surveys and we carried out three Focus Group Discussions with a maximum variation sample from across the UK adult population. The discussions covered the broader topic of ‘Inequalities and mental health during the Coronavirus pandemic in the UK’ and took place online between April and August 2020. Focus Groups transcripts were analysed using thematic analysis in NVIVO. Cross-sectional survey data were analysed using STATA for descriptive statistics. Three broad main themes emerged, each supporting a number of sub-themes: (1) Impacts of the pandemic; (2) Moving forward: needs and recommendations; (3) Coping mechanisms and resilience. Findings showed that participants described their experiences of the pandemic in relation to its impact on themselves and on different groups of people. Their experiences illustrated how the pandemic and subsequent measures had exacerbated existing inequalities and created new ones, and triggered various emotional responses. Participants also described their coping strategies and what worked and did not work for them, as well as support needs and recommendations for moving forward through, and out of, the pandemic; all of which are valuable learnings to be considered in policy making for improving mental health and for ensuring future preparedness. The pandemic is taking a long-term toll on the nations’ mental health which will continue to have impacts for years to come. It is therefore crucial to learn the vital lessons learned from this pandemic. Specific as well as whole-government policies need to respond to this, address inequalities and the different needs across the life-course and across society, and take a holistic approach to mental health improvement across the UK.

Open Access PDF

Concepts Keywords
Coronavirus Adult population
Deaths Coronavirus
Global Covid-19
Therapy Inequalities
Mental health
Social determinants
United Kingdom


Type Source Name
pathway KEGG Coronavirus disease
disease MESH COVID-19
disease VO time
disease VO vaccine
disease VO population
pathway REACTOME Reproduction
drug DRUGBANK Pumactant
drug DRUGBANK Creatinolfosfate
drug DRUGBANK Guanosine
disease MESH loneliness
disease VO frequency
disease VO report
disease IDO intervention
disease MESH causes
disease MESH mental deterioration
disease VO protocol
drug DRUGBANK Coenzyme M
drug DRUGBANK Serine
drug DRUGBANK Polyethylene glycol
disease MESH domestic violence
disease MESH Long COVID
disease MESH infection
drug DRUGBANK Esomeprazole
drug DRUGBANK Hyaluronic acid
disease IDO country
disease MESH suicide
disease MESH mental illness
disease VO company
disease MESH Marital status
disease MESH uncertainty
disease VO ReCOV
disease IDO process
disease MESH death
drug DRUGBANK Trestolone
disease MESH psychological distress
drug DRUGBANK Etoperidone
disease MESH morbidity
disease MESH chronic diseases
drug DRUGBANK Isoxaflutole
disease MESH suicidal ideation
disease MESH dementia
drug DRUGBANK Troleandomycin
drug DRUGBANK Methyl isocyanate
drug DRUGBANK Gold
disease MESH emerging infectious diseases
disease VO Equity
disease MESH emergency

Original Article

(Visited 1 times, 1 visits today)